The recent description of somatic cell reprogramming to an embryonic stem (ES) cell-like phenotype, termed induced pluripotent stem (iPS) cell technology, presents an exciting potential venue toward cell-based therapeutics and disease models for neurodegenerative disorders. Two recent studies (Dimos et al. and Ebert et al.) describe the initial characterization of neurodegenerative disease patient-derived iPS cell cultures as proof of concept for the utility of this technology.
Stem cell-based therapies for neurodegenerative disorders are particularly attractive, given the limited regenerative capacity of the mammalian central nervous system. However, most potential sources of cell therapeutics, such as fetal-derived primary neurons, human ES cells, and endogenous neural stem cells, are associated with ethical controversy or present technical limitations. Furthermore, cell therapies from heterologous sources can be subject to graft rejection, and attempts to generate immunologically compatible stem cell therapies by nuclear transplantation from human cells (''therapeutic cloning'') have thus far been unsuccessful. In this context, Shinya Yamanaka's group devised a novel cellbased screen for the identification of genes that could directly reprogram skin fibroblasts to pluripotency (Okita et al., 2007; Takahashi and Yamanaka, 2006) . Yamanaka and colleagues had assembled a list of 23 candidate ''stemness'' genes implicated in promoting or maintaining pluripotency, and although transduction of any single candidate was ineffective, a minimal set of four genesOct4, Sox2, Klf4, and c-Myc-appeared sufficient for reprogramming to an iPS cell phenotype (Okita et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al., 2007) . Differentiation of these iPS cell cultures generated a variety of cell fates in vitro and in vivo, and rodent iPS cells transplanted into blastocysts could contribute to all tissues, including the germline. The subsequent successful generation of human iPS cells from skin fibroblasts opened the door for iPS cellbased therapies (Takahashi and Yamanaka, 2006; Yu et al., 2007) .
To this end, Dimos et al. (Dimos et al., 2008) obtained fibroblast lines from two elderly siblings with early or late manifestations of ALS, including weakness of the arms and legs, caused by a diseaseassociated mutation in the superoxide dismutase (SOD1) gene. Patient fibroblasts were retrovirally transduced with the Yamanaka group's four-gene cocktail, and after 3 weeks, colonies arose with a distinctive rounded ES cell-like morphology and displaying typical ES cell markers such as alkaline phosphatase activity and expression of SSEA-3, SSEA-4, TRA 1-60, and TRA 1-81. These iPS cell lines appeared to be pluripotent in vitro, as they could be spontaneously differentiated into representative phenotypes of the three embryonic germ cell layers. Furthermore, using an established protocol that recapitulates aspects of endogenous spinal motor neuron specification, including the application of retinoic acid and an agonist of the Sonic Hedgehog signaling pathway, iPS cells could be driven to a spinal motor neuronlike phenotype. These cells expressed key motor neuron markers, including HB9 and ISLET1/2, although they were not functionally characterized for basic neuronal properties. A key limitation of the study is that no phenotypic changes that may correspond to the disease process were described.
The study from Ebert et al. (Ebert et al., 2008 ) took a very similar approach to address the major spinal motor neuron degenerative disorder of childhood, spinal muscular atrophy, typically caused by a genetic mutation in the survival motor neuron-1 (SMN1) gene. Skin fibroblasts from a single patient and control (his unaffected mother) were transduced with a cocktail of lentiviral constructs (Oct4, Sox2, Nanog, LIN28), leading to the generation of iPS cell lines, and these could in turn be differentiated to a variety of cell types, including cells with a spinal motor neuron phenotype that harbor the SMN1 mutation. Ebert et al. (Ebert et al., 2008) went on to culture the iPS cell culturederived motor neurons for an additional 2 weeks and reported a specific reduction in the accumulation and size of these cells in patient cultures versus normal controls. In addition, the patient iPS cells displayed a predicted deficiency in nuclear SMN protein aggregates, termed gems. Treatment of the cells with either of two known chemical inducers of SMN protein expression-valproic acid or tobramycin-suppressed this phenotype. It will be of interest to determine whether patient iPS cell-derived motor neuron reduction can be similarly suppressed by these compounds or by novel SMN inducers. Furthermore, although encouraging, it will be important to replicate these data, which have been derived from single-patient iPS cell cultures, as human ES cell lines display substantial phenotypic diversity, and given the genetic heterogeneity of these individuals. Ultimately, suppression of patient iPS cell culture-associated phenotypes by repair of the underlying genetic mutation would strongly validate these models.
Despite these concerns, iPS cell cultures offer a potentially powerful approach to neurodegenerative disease modeling. Existing animal models of neurodegeneration do not recapitulate key aspects of disease: for instance, mice harboring genetic mutations that are associated with familial forms of Parkinson's disease fail to display a selective loss of midbrain substantia nigra dopamine neurons (Abeliovich and Flint Beal, 2006), possibly a consequence of species-specific aspects of disease. In the context of SMA, pathogenesis due to SMN1 mutation requires coexpression of the nearly identical SMN2 gene, but the latter gene is absent in model organisms. An additional limitation of existing animal and cell models of neurodegenerative disease is that they are generally based on rare familial inherited forms of these disorders. For instance, although SOD1 mutations account for less than 1% of all ALS cases, nearly all drug discovery efforts for ALS have been based on this model.
Although the two studies cited here focused on familial forms of neurodegenerative diseases, iPS cell-derived neurons could also be generated from patients with common ''sporadic'' forms of these diseases. The etiology of ''sporadic'' disease is unclear, and there is evidence for both environmental causes as well as complex multigenic effects. Studies to address this issue are typically based on epidemiological approaches, but iPS cell models offer an alternative. iPS cell reprogramming is believed to maintain genomic content, but to erase epigenetic signatures, as would arise from environmental or cell-intrinsic stimuli (Okita et al., 2007; Takahashi et al., 2007; Takahashi and Yamanaka, 2006) . Thus, if common ''sporadic'' ALS is primarily due to complex multigenic causes, then reprogrammed cells may retain an underlying propensity for disease. In contrast, nongenetic or epigenetic causes that are not encoded in the host genome may be erased through reprogramming, and iPS cell generation and neuronal differentiation may ''rejuvenate'' the cells and thus be protective in cell-based therapies.
It remains to be determined whether typical neurodegenerative disease traits can be observed in the context of iPS cell-based culture models of these disorders. At a molecular level, such as disease-associated protein expression levels or global gene expression analysis, it is possible that patient iPS-derived neuron cultures will recapitulate patient phenotypes. But for late-onset neurodegenerative diseases, reprogrammed patient iPS cell-derived neurons are unlikely to show typical patient brain pathology, such as Lewy bodies in PD.
The generation of iPS cells from a patient's own skin fibroblasts would potentially allow for a plentiful source of cell therapeutics for autotransplantation and would likely mitigate the problem of immune rejection. Furthermore, iPS cell technology largely circumvents political, ethical, and logistical roadblocks previously associated with human nuclear transplantation (''therapeutic cloning''). However, other concerns remain, such as the risk of cancer. The Yamanaka group's initial studies indicated an increased risk of tumors in iPS cell-derived mouse progeny, and this correlated with vector-encoded c-Myc expression in the tumor cells (Okita et al., 2007) . Indeed, Dimos et al. (Dimos et al., 2008) observe maintained expression of the virally encoded c-Myc oncogene in the iPS cell lines. However, recent studies have shown that c-Myc transduction is expendable for reprogramming (Nakagawa et al., 2008; Yu et al., 2007) . Retroviral vectors used for iPS cell generation can also induce tumorigenesis upon integration into the host genome, but this can be circumvented using nonintegrating vectors (Stadtfeld et al., 2008) .
The majority of prior clinical experience with cellular therapeutics in the CNS has been based on fetus-derived cells from postmortem human embryos for PD patients (Freed et al., 2001 ). The results have been largely disappointing: symptomatic benefit appears variable, and bothersome dyskinesias can be seen (Freed et al., 2001) . As fetus-derived dopaminergic cell therapies are obtained at a relatively late stage of development and in limited numbers, it is possible that iPS cell-derived or other stem cell-based therapeutics would be more effective. Promising results come from an animal study in which rodent iPS cell-derived neurons improve symptoms of rats with Parkinson's disease (Wernig et al., 2008) . In contrast, the problem of cell replacement for spinal motor neurons appears logistically daunting, given that these cells must extend and correctly wire meter-long axons. Transplanting cell therapeutics as support cells, rather than as replacement neurons, is a potential alternative mode of cell therapy.
A final concern is that iPS cell-derived therapeutics will recapitulate the patient's disease process, due to their genetic propensity. In the context of single-gene disorders, such changes may theoretically be genetically repaired in vitro prior to transplantation, as suggested by a study with a rodent model of sickle cell anemia (Hanna et al., 2007) . For disorders of aging, the relatively brief lifetime of the reprogrammed cells may sufficiently delay an intrinsic pathogenic program. However, cell-extrinsic factors in the host patient CNS environment may promote pathogenesis in therapeutic transplanted cells, as suggested in analyses of autopsy material from PD patients previously transplanted with fetus-derived dopamine neurons (Li et al., 2008) . Despite these potential pitfalls, iPS cell technology, although nascent, represents a remarkable step forward toward stem cell therapeutics and models for neurodegenerative disorders, for which no current therapies significantly modify disease progression.
